Harbour Biomed’s Porustobart Combo Shows Promise in HCC Treatment, ASCO Presentation Reveals
China-based Harbour Biomed (HKG: 2142) has announced the publication of results from a Phase Ib...
Ascentage Pharma’s Olverembatinib Earns Breakthrough Designation for SDH-Deficient GIST
The China’s Center for Drug Evaluation (CDE) has granted breakthrough therapy designation (BTD) to olverembatinib,...
Abbisko Therapeutics Reports Positive Phase Ib Results for ABSK021 at ASCO
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) is poised to announce positive results from...
Shanghai Yizhong’s Paclitaxel Micelles Data to be Presented at ASCO Annual Meeting
Shanghai Yizhong Pharmaceutical Co., Ltd (SHA: 688091), a China-based pharmaceutical company, has announced that clinical...
SAMR Imposes Penalties on Grand Pharma and WuHan Huihai for Monopoly Agreements
The State Administration for Market Regulation (SAMR) has imposed administrative penalties on Grand Pharmaceutical Group...
Ascentage Pharma to Present Clinical Results of Four Oncology Drugs at Medical Conference
Suzhou-based Ascentage Pharma (HKG: 6855) has announced its intention to present the clinical results of...
Hainan Province and NHSA Partner to Enhance Medical Insurance Industry with Real-World Data
The government of Hainan province has entered into a strategic partnership with the National Healthcare...
BeiGene Presents Groundbreaking Clinical Data at ASCO Annual Meeting
China-based BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) announced the presentation of new data at...
Shanghai Market Regulation Bureau Targets Unfair Competition in Pharmaceutical Sector
The Shanghai market regulation bureau has released a document aimed at cracking down on unfair...
TianLong Science and Technology Expands into Northern Thailand with Hepatitis Diagnostics
Xi’an-based med-tech firm TianLong Science and Technology Co., Ltd has reportedly entered into a supply...
Chia Tai Tianqing’s TQ-B3525 Heads for Priority Review for Recurrent Follicular Lymphoma
The Center for Drug Evaluation (CDE) website has indicated that Chia Tai Tianqing’s TQ-B3525, a...
Sanofi Launches Soliqua for Type 2 Diabetes Treatment in China
French pharmaceutical major Sanofi (NASDAQ: SNY) has announced the official market launch of Soliqua (insulin...
GenScript’s Legend Biotech Files Type II Variation Application for Carvykti with EMA
China-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) has announced that its subsidiary,...
Takeda and HutchMed’s Fruquintinib Receives Priority Review Status from FDA
Takeda (TYO: 4502) and HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) have provided an update...
China’s NHC Releases Fourth List of Pediatric Priority Drugs to Boost Development
The National Health Commission (NHC) of China has published its fourth list of pediatric drugs...
Sichuan Kelun Pharmaceutical to Present Clinical Data on RET Inhibitor and ADC at ASCO
Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422), a China-based pharmaceutical company, has unveiled plans to...
Lancet Study Reveals Dalian’s Cancer Survival Rates Compared to US
A recent study published in The Lancet has conducted a comparative analysis of cancer mortality...
BioRay Pharmaceutical’s LIV-1 Targeted ADC BRY812 Files IND in China
Shanghai-based BioRay Pharmaceutical Co., Ltd has announced that an investigational new drug (IND) filing has...
Accropeutics Receives HREC Approval for AC-201 Phase I Trial
Suzhou-based Accro Bioscience (Suzhou) Limited (Accropeutics) has announced that it has received approval from the...
Vcanbio Initiates Phase II Clinical Study for Dental Pulp Stem Cell Injection in Periodontitis
China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced the imminent initiation...